Akebia Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AKBA research report →
Companywww.akebia.com
Akebia Therapeutics, Inc. , a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients.
- CEO
- John Butler
- IPO
- 2014
- Employees
- 181
- HQ
- Cambridge, MA, US
Price Chart
Valuation
- Market Cap
- $270.94M
- P/E
- -13.15
- P/S
- 1.17
- P/B
- 9.85
- EV/EBITDA
- 38.19
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 80.87%
- Op Margin
- 2.28%
- Net Margin
- -8.83%
- ROE
- -62.72%
- ROIC
- 2.63%
Growth & Income
- Revenue
- $236.20M · 47.46%
- Net Income
- $-5,345,000 · 92.30%
- EPS
- $-0.02 · 93.70%
- Op Income
- $23.50M
- FCF YoY
- 267.09%
Performance & Tape
- 52W High
- $4.08
- 52W Low
- $0.88
- 50D MA
- $1.36
- 200D MA
- $1.95
- Beta
- 0.35
- Avg Volume
- 3.33M
Get TickerSpark's AI analysis on AKBA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 1, 26 | Vickers Philip J. | other | 214,400 |
| Apr 1, 26 | Vickers Philip J. | other | 0 |
| Mar 4, 26 | Butler John P. | buy | 69,270 |
| Feb 2, 26 | Malabre Richard C | sell | 36,142 |
| Feb 2, 26 | Malabre Richard C | sell | 13,382 |
| Feb 2, 26 | Grund Nicholas | sell | 53,585 |
| Feb 2, 26 | Grund Nicholas | sell | 31,244 |
| Feb 2, 26 | Burke Steven Keith | sell | 21,582 |
| Feb 2, 26 | Burke Steven Keith | sell | 25,375 |
| Feb 2, 26 | Burke Steven Keith | sell | 20,701 |
Our AKBA Coverage
We haven't published any research on AKBA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate AKBA Report →